A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jack Wells, MD
Palmetto Retina Center
Principal Investigator - Jennifer Sun, MD, MPH
Joslin Diabetes Center
Principal Investigator - Raj Maturi, MD
Midwest Eye Institute
Principal Investigator - Victor Gonzalez, MD
Valley Retina Institute, PA
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Retina Vitreous Associates Medical Group
Beverly Hills, California, United States
- Raj K. Maturi, Md Pc
Indianapolis, Indiana, United States
- Beetham Eye Institute
Boston, Massachusetts, United States
- Palmetto Retina Center
West Columbia, South Carolina, United States
- Valley Retina Institute, Pa
McAllen, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Jul 2014
- Primary completion
- 4 Jun 2015
- Completion
- 4 Jun 2015
- Last update posted
- 3 Mar 2017
- Registered enrollment
- 14
- Registry id
- NCT02193113
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.